How investors should approach Amazon after their earnings release with Gene Munster, Piper Jaffray. » Read More
General Mills raised its dividend by 8 percent, reported positive earnings, but gave disappointing guidance, says Mad Money host Jim Cramer. Ken Powell, General Mills chairman & CEO, offers insight on where he thinks his company is headed.
Mad Money host Jim Cramer explains why he thinks Ventas can withstand any ruling on Obamacare; and Debra Cafaro, Ventas chairman & CEO, discusses how her company has held such a great track record for the last 12 years.
Mad Money host Jim Cramer takes a look at how the markets behaved in 1994 when everyone thought a "personal cliff" was on its way, and explains why he thinks the market is in a better position now.
The Fast Money traders share their final trades of the day.
The Fast Money traders think if investors want to take a so-called "punt" in the trading world, Research In Motion looks interesting ahead of its earnings tomorrow.
Is Romney talking about the economy and is he connecting with high-anxiety voters about the economy? Discussing Romney's campaign focus, with Governor Bob McDonnell (R-VA). "Mitt Romney has created over 100,000 jobs in the private sector, he gets the American dream, and he will inspire people to grow," says McDonnell.
Google has announced its new tablet, "Nexus 7," and that it will sell for $199, reports CNBC's Jon Fortt. The Fast Money traders share their opinions.
Shares of Arena Pharmaceuticals spiked on news the FDA approved its anti-obesity drug, with the Fast Money traders; and discussing how tomorrow's ruling on the health care reform could impact the biotech sector, with Mark Schoenebaum, ISI.
The biotech sector is up more than 1 percent today, and discussing what investors can expect after tomorrow's health care reform ruling, with ISI's biotech and pharmaceuticals major analyst Mark Schoenebaum. "If tomorrow the whole bill is struck down, technically, earnings and revenue estimates for all of biotech and all of pharma companies are going to go up," says Schoenebaum.
The Fast Money traders take a look at today's biggest market movers.
A month after Facebook’s botched initial public offering, Wall Street analysts released more than a dozen highly anticipated reports detailing what they think of the company’s potential. For one analyst, the answer is a “money-making opportunity.”
Housing stocks are moving higher in the past two days, with the Fast Money traders; and David Rosenberg, Gluskin Sheff, explains why he is not sold on the housing turnaround.
Stocks finished higher in relatively thin trading Wednesday, led by the energy sector and following a pair of better-than-expected economic reports, but investors remained cautious ahead of the two-day EU summit later this week.
Check out which companies are making headlines after the bell Wednesday:
Jack Lief, Arena Pharmaceuticals CEO, discusses what the drug-maker's new anti-obesity drug will mean for its bottom-line, with CNBC's Seema Mody.
Despite Moody's recent downgrade of Wall Street banks, Gerard Cassidy, bank analyst at RBC Capital, says US banks are "strong" and will soon be paying more to investors.
The rich seemed to have lost their rose-colored glasses. Why? CNBC's Robert Frank reports.
Facebook’s recent IPO, the sharp drop in its share price, and the delay of other IPOs in the pipeline have reignited questions about why more U.S. companies aren’t going public and what’s behind the 15-year decline in the number of publicly traded companies.
Take a look at some of Wednesday's midday movers:
With a key European Union summit looming, the euro may not have priced in a truly dramatic outcome.